Detalhe da pesquisa
1.
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 90(3): 485-493, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37852306
2.
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
J Eur Acad Dermatol Venereol
; 37(2): 348-355, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36300769
3.
Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey.
Dermatol Ther (Heidelb)
; 13(6): 1329-1346, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37183192
4.
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
J Rheumatol
; 49(7): 694-699, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35428720
5.
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
Dermatol Ther (Heidelb)
; 12(1): 61-78, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34704231
6.
Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
Dermatol Ther (Heidelb)
; 12(1): 79, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34989998